Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding CDP-1050 as a paradigm for the treatment of heart failure, satisfaction of the medical community and regulatory authorities as to the
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... researchers have identified a class of high-strength metal alloys ... smaller and more responsive. The alloys could be ... loudspeakers, and components that boost the performance of medical ... engines. While these nanostructured metal alloys are not ...
... Reportlinker.com announces that a new market research report ... Three Alternative Scenarios of the Future In Vitro ... http://www.reportlinker.com/p0363585/Three-Alternative-Scenarios-of-the-Future-In-Vitro-Diagnostics-Market-through-2018.html This report is ... and R&D executives. The report is designed to ...
... N.J., March 9, 2011 Palatin Technologies, Inc. (NYSE Amex: ... at the ROTH 23rd Annual OC Growth Stock Conference on ... conference will be held at the Ritz Carlton Laguna Niguel ... President and Chief Executive Officer of Palatin Technologies, will provide ...
Cached Biology Technology:Rutgers researchers identify materials that may deliver more 'bounce' 2Reportlinker Adds Three Alternative Scenarios of the Future In Vitro Diagnostics Market through 2018 2
(Date:4/16/2014)... ,, Imagine you cannot move your eyes up, and you cannot ... tilted upward so that your eyes look straight when they are ... be corrected to allow people a normal position of their head. ... why this happens. , In a paper published in the April ...
(Date:4/16/2014)... bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder ... long considered it to be essentially an affliction of primary ... brainstem that control muscle movement. , But in a new ... Neuron , a team of scientists at the University ...
(Date:4/16/2014)... array of finger-like projections called microvilli covers the ... University researchers have now discovered how intestinal cells build ... and defending against pathogens. The findings, published April 10 ... for adhesion molecules in brush border assembly and increase ...
Breaking Biology News(10 mins):Researchers track down cause of eye mobility disorder 2Mutant protein in muscle linked to neuromuscular disorder 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 3
... A study led by St. Jude Children,s Research Hospital has ... of nerve cells in amyotrophic lateral sclerosis (ALS), also known ... same mutation occurred in both genes and led to the ... an essential role in normal RNA functioning and have also ...
... An international group of researchers has discovered seven ... with increased risk of age-related macular degeneration (AMD), a ... network of international investigators representing 18 research groups, also ... which is published online in Nature Genetics ...
... CHAMPAIGN, Ill. A study published in the journal ... late 1800s in West Central Illinois. The study could not ... says a co-author of the new research., Charles Robertson, a ... and the University of Illinois, was one of the first ...
Cached Biology News:2 new genes linked to amyotrophic lateral sclerosis and related disorders 22 new genes linked to amyotrophic lateral sclerosis and related disorders 3International consortium discovers seven new genomic regions associated with AMD 2International consortium discovers seven new genomic regions associated with AMD 3Illinois town provides a historical foundation for today's bee research 2
... Immulon 2HB ELISA strips, high binding ... affinity for hydrophilic proteins and complexes. ... for reagent injection while providing the ... Each strip accomodates 12 wells., ...
...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
Biology Products: